GeneDx Holdings Faces Class Action Lawsuit After 49% Stock Plunge

In a dramatic turn of events, GeneDx Holdings (NASDAQ: WGS) is at the center of a securities class action lawsuit spearheaded by the esteemed legal firm Hagens Berman Sobol Shapiro LLP. Following a staggering 49% drop in stock price after the company's First Quarter 2026 earnings report, the firm is urging investors who suffered significant losses to take notice of their legal options. The deadline for filing as a lead plaintiff in this class action is set for August 3, 2026.

The crux of the lawsuit revolves around allegations that GeneDx and its executives misled investors regarding the acquisition of Fabric Genomics, suggesting that it would enhance operational efficiency and profitability. However, the reality was starkly different. On May 4, 2026, the company disclosed its Q1 results, which not only showcased a tenfold increase in net loss from the previous year but also revealed significant impairment charges tied to the Fabric Genomics acquisition amounting to $31.2 million. This figure highlighted a drastic disconnect between projected and actual financial performance.

The fallout from this situation was intensified by the disappointing revenue results from the Fabric Genomics division, which reported a revenue miss of $2.5 million. The alleged misrepresentation by GeneDx regarding the benefits of this acquisition raised eyebrows, as it positioned the merger as fundamental to the company's future growth narrative. In light of this, the lawsuit asserts that investors were enticed by misleading claims only to experience financial devastation following the revelation of the company's true financial health.

Adding to the turmoil, GeneDx's Annual Recurring Revenue (ARR) fell short of expectations by about $200 million, a drastic shift attributed to an unfavorable change in product mix. The anticipated revenue growth for both exome and genome segments was slashed from previous projections, with the company revising its 2026 revenue guidance downward by 12%.

In response to the crisis, GeneDx appointed Mark Gardner as its new President. This leadership change is under scrutiny by Hagens Berman as they investigate whether there are links between this transition and the failures that led to the substantial stock decline. Reed Kathrein, a partner at Hagens Berman leading the investigation, stated, “The allegations suggest that investors were sold a vision of technological synergy, only to face a substantial impairment charge instead.”

Given the substantial losses incurred by investors, Hagens Berman encourages anyone impacted to contact them as soon as possible to explore legal avenues. The firm is not only focused on representing investors but also urges whistleblowers with inside information about GeneDx's operations to consider their options under the SEC Whistleblower program, which offers incentives for individuals who provide original information leading to successful SEC recoveries.

About Hagens Berman: This law firm is renowned for its advocacy in corporate accountability, helping both small and large groups of stakeholders achieve substantial recoveries for losses suffered due to corporate wrongdoing. With an impressive track record surpassing $2.9 billion in financial recoveries, Hagens Berman stands as a beacon for investors seeking justice in the wake of corporate deception.

As the situation surrounding GeneDx Holdings continues to unfold, all eyes remain on how the class action lawsuit develops. Investors and shareholders anxious about their financial future are advised to follow the proceedings closely and stay in touch with legal representatives who can provide vital updates and support throughout this challenging time.